跳至主要内容
临床试验/ISRCTN53054042
ISRCTN53054042已完成未知

Supraphysiologic hydrocortisone in severe acute pancreatitis: a multicentre, randomised, double-blind, placebo-controlled trial

Helsinki University Central Hospital (EVO) (Finland)0 个研究点目标入组 150 人开始时间: 2008年12月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients with severe acute pancreatitis
  • 2. Despite adequate fluid resuscitation (pulmonary capillary wedge pressure [PCWP] greater than 12 or central venous pressure [CVP] greater than 8 mmHg) presence of shock requiring vasopressor (norepinephrine greater than 0.2 µg/kg/min) support for at least one hour
  • 3. Aged 18 to 65 years, both genders

排除标准

  • 1. Lack of written informed consent from patient or next of kin
  • 2. Time from admission to hospital over seven days
  • 3. Vasopressor support continued without interruption over 48 hours
  • 4. Aged less than 18 years or greater than 65 years
  • 5. Pregnancy or breastfeeding
  • 6. More than two previous attacks of acute pancreatitis
  • 7. Chronic pancreatitis or presence of complication after previous acute pancreatitis like pseudocyst
  • 8. Hepatitis B, hepatitis C or human immunodeficiency (HIV) infection
  • 9. Presence of acute infection (urinary, pulmonary, skin or soft-tissue infection)
  • 10. Major abdominal, thoracic or vascular surgery within last 30 days
  • 11. Severe chronic liver disease
  • 12. Severe heart failure

研究者

发起方
Helsinki University Central Hospital (EVO) (Finland)

相似试验